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A B S T R A C T
Purpose
To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving
surgery and tamoxifen in women age  70 years with early-stage breast cancer.
Patients and Methods
Between July 1994 and February 1999, 636 women (age  70 years) who had clinical stage I (T1N0M0
according to TNM classification) estrogen receptor (ER) –positive breast carcinoma treated by lumpectomy
were randomly assigned to receive tamoxifen plus radiation therapy (TamRT; 317 women) or tamoxifen
alone (Tam; 319 women). Primary end points were time to local or regional recurrence, frequency of
mastectomy, breast cancer–specific survival, time to distant metastasis, and overall survival (OS).
Results
Median follow-up for treated patients is now 12.6 years. At 10 years, 98% of patients receiving
TamRT (95% CI, 96% to 99%) compared with 90% of those receiving Tam (95% CI, 85% to 93%)
were free from local and regional recurrences. There were no significant differences in time to
mastectomy, time to distant metastasis, breast cancer–specific survival, or OS between the two
groups. Ten-year OS was 67% (95% CI, 62% to 72%) and 66% (95% CI, 61% to 71%) in the
TamRT and Tam groups, respectively.
Conclusion
With long-term follow-up, the previously observed small improvement in locoregional recurrence
with the addition of radiation therapy remains. However, this does not translate into an advantage
in OS, distant disease-free survival, or breast preservation. Depending on the value placed on local
recurrence, Tam remains a reasonable option for women age  70 years with ER-positive
early-stage breast cancer.
J Clin Oncol 31:2382-2387. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Radiation therapy (RT) after breast-conserving sur-
gery decreases the risk of ipsilateral breast recurrence
(IBTR). Several studies have suggested that there
exists a favorable subgroup of patients in whom
irradiation may not provide meaningful overall ben-
efit, including but not limited to older women with
smaller estrogen receptor (ER) –positive cancers
treated with antihormonal therapy.1-5 To test this
hypothesis, the Cancer and Leukemia Group B
(CALGB) initiated CALGB 9343, a randomized trial
comparing the efficacy of tamoxifen alone (Tam)
with tamoxifen plus RT (TamRT) in older women
with ER-positive, clinical stage I breast cancer.
When reported in 2004 (median follow-up, 5
years),6 the 5-year incidence of IBTR or regional
nodal recurrence was 4% for patients receiving Tam
and 1% for those receiving TamRT. There was no
difference in survival, time to distant metastasis, or
ultimate breast-preservation rate. Examining Medi-
care data through 2007, Soulis et al7 found that our
report had little impact, with the use of irradiation
only slightly diminishing in this population. Because
it was possible that with longer-term follow-up our
results might not persist, we performed this long-
term analysis to address these concerns.
PATIENTS AND METHODS
The methods of this study have been previously de-
scribed.6 CALGB 9343 was designed in cooperation with
the Eastern Cooperative Oncology Group (ECOG) and
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Radiation Therapy Oncology Group (RTOG). Local institutional review
boards reviewed and approved the study in compliance with the Declaration of
Helsinki. Written informed consent was obtained from all patients. An inde-
pendent data and safety monitoring committee provided oversight. The
CALGB Statistical Center managed data collection, and data quality was en-
sured by the study chairperson and statistical center review. CALGB statisti-
cians performed the statistical analyses. The CALGB quality-assurance
program has been previously described.6
Patient Selection
Women age  70 years with clinical stage I, ER-positive breast cancer
and no history of cancer other than in situ cervical or nonmelanoma skin
cancer within 5 years were eligible. Initial eligibility criteria included breast
cancers up to 4 cm regardless of estrogen receptor status, but this was reduced
in August 1996 to  2 cm (T1) with ER-positive or indeterminate receptor
status. Patients were required to have clinically negative axillae.
Treatment
At entry, patients were randomly assigned (1:1 ratio) to receive Tam
or TamRT.6 Random assignment was stratified by age ( 75 v  75 years)
and axillary dissection (yes v no). Patients were observed every 4 months
for 5 years and yearly thereafter. This study did not rigorously capture
tamoxifen discontinuation.
Local therapy. All women underwent lumpectomy with a clear margin
(absence of tumor at the inked margin). Axillary node dissection was allowed
but not encouraged. RT included tangential fields to the entire breast followed
by an electron boost to the lumpectomy site.6
Tamoxifen. All women received 20 mg of tamoxifen per day for 5 years,
initiated either during or after irradiation. Adjuvant hormonal treatment
beyond 5 years was discretionary.
Study End Points
The primary study end points were time to locoregional recurrence,
frequency of mastectomy for recurrence, breast cancer–specific survival, time
to distant metastasis, and overall survival (OS). IBTR was defined as any cancer
in the ipsilateral breast. Regional recurrence was defined as any recurrence in
the ipsilateral supraclavicular, infraclavicular, or axillary nodes. Secondary end
points were cosmetic results, as judged by physician and patient, and adverse
effects such as breast pain and skin changes.
Actuarial Survival
The expected proportion of women in this study who would be alive at
each year after random assignment was found assuming the women were
randomly sampled from women of the same age in the general population. We
used the 2001 period life table of the US Social Security Administration (ap-
proximate middle of follow-up for this study). We compared actual survival
proportion and its confidence limits over time after random assignment of
women in the study with their actuarial survival distribution.
Statistical Analysis
This study was designed with 90% power to detect a (one-sided) differ-
ence in 3-year locoregional recurrence between Tam at 16% versus TamRT at
9%. The target sample size was 572 patients; however, we overaccrued the
study to 647 to compensate for the smaller than expected number of ob-
served events.
The primary comparison of treatment arm on time-to-event end
points used proportional hazards modeling adjusted for tumor size, pa-
tient age, and axillary dissection. Hazard ratios (HRs), constructed as
TamRT to Tam, and their 95% CIs were taken from these multivariate
models. Distributions of time-to-event variables were estimated according
to the Kaplan-Meier method,8 and distributions were compared between
treatment groups by means of the log-rank test.9 All P values are two sided
and unadjusted for multiplicity. In terms of survival, the study was not
powered to prove noninferiority.
RESULTS
The study was initiated by the CALGB (July 1994) and by the RTOG
and ECOG (December 1996). Enrollment ended in February 1999
with 647 women: CALGB, 307; ECOG, 112; and RTOG, 228 (Fig 1).
Eleven patients (2%) never began protocol treatment. Statistical anal-
yses used a modified intent-to-treat approach that included all 636
patients who began protocol treatment: 317 with TamRT and 319
with Tam. Before the eligibility change, 10 patients with ER-negative
tumors and 13 patients with tumors  2 cm were entered. Baseline
characteristics of the women were similar in the two groups (Appen-
dix Table A1, online only).
As of January 2011, median follow-up was 12.6 years (maximum,
16.5 years). Of the 636 treated patients, 335 (53%) survived at least 10
years, 227 of whom remain in active follow-up. Because the observed
treatment effect was similar when assessed by both log-rank and mul-
tivariate methods, we quote the P values from only the log-rank test.
Time to Locoregional Recurrence
As compared with the Tam group, the TamRT group experi-
enced a significantly longer time to locoregional recurrence (ob-
served HR, 0.18; 95% CI, 0.07 to 0.42; P  .001; Fig 2). At 10 years,
90% of patients in the Tam group (95% CI, 85% to 93%) compared
with 98% in the TamRT group (95% CI, 96% to 99%) were free
from locoregional recurrence. Thirty-two women in the Tam
group experienced locoregional recurrence; of these, 20 had only
IBTR; six, IBTR with distant metastasis; five, only axillary recur-
rence; and one, both IBTR and axillary recurrence. Six women in
the TamRT group experienced locoregional recurrence; all six were
IBTRs (Table 1). At 10 years, 91% in the Tam group (95% CI, 87%
to 94%) compared with 98% in the TamRT group (95% CI, 96% to
99%) were free from local (IBTR) recurrence.
There were no axillary recurrences among the 244 women who
underwent initial axillary dissection. Among those who did not un-
dergo axillary dissection, there were no axillary recurrences in the













Excluded (n = 11)
  Did not meet (n = 4)
     inclusion criteria
  Other reasons; (n = 7)
    unknown
Fig 1. CONSORT diagram. Tam, tamoxifen alone; TamRT, tamoxifen plus
radiation therapy.
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Treatment of IBTR
Six patients receiving TamRT and 27 receiving Tam had in-breast
recurrences (IBTRs). Of these, four (TamRT) and 10 (Tam) under-
went mastectomy. One patient in the TamRT arm underwent
lumpectomy without RT; 13 in the Tam arm underwent lumpectomy
(four without RT, eight with RT, and one unknown RT).
Time to Mastectomy
Time to mastectomy did not differ significantly between the two
treatment groups (observed HR, 0.50; 95% CI, 0.17 to 1.48; P  .17;
Fig 3). The 10-year probability of not undergoing mastectomy was
98% (95% CI, 96% to 99%) in the TamRT group and 96% (95% CI,
93% to 98%) in the Tam group.
Time to Distant Metastasis
Time to distant metastasis did not differ significantly between the
two treatment groups (P  .50; Fig 4); distant relapse occurred in 21
patients in the TamRT group (13 have died as a result of breast cancer)
and 16 in the Tam group (eight have died as a result of breast cancer).
The 10-year probability of freedom from distant metastasis was 95%
(95% CI, 92% to 97%) in the TamRT group and 95% (95% CI, 91% to
97%) in the Tam group (observed HR, 1.20; 95% CI, 0.63 to 2.32).
Survival
Of the 636 women in the trial, there were 334 deaths: 166 in the
TamRT arm and 168 in the Tam arm (HR, 0.95; 95% CI, 0.77 to 1.18).
The respective 10-year estimates of OS were 67% (95% CI, 62% to
72%) and 66% (95% CI, 61% to 71%; Fig 5). Only 21 of the deaths
(6.3%) resulted from breast cancer: 13 in the TamRT arm and eight in
the Tam arm (HR, 1.55; 95% CI, 0.64 to 3.74). The respective 10-year
breast cancer–specific survival estimates (Appendix Fig A1, online
only) were 97% (95% CI, 94% to 99%) and 98% (95% CI, 95% to
99%). Figure 6 shows survival proportion over time for women in this
study (both groups combined) in comparison with the expected sur-






































TamRT 317 261 162 7
Tam 319 243 144 2
Fig 2. Time to local or regional recurrence. HR, hazard ratio; Tam, tamoxifen
alone; TamRT, tamoxifen plus radiation therapy.
Table 1. Clinical Outcome: Recurrence and Death
Treated Patients TamRT Arm Tam Arm Total
Total 317 319 636
Recurrence 23 42 65
Local or regional  distant 6 32 38
IBTR alone 2 20 22
Axilla alone 0 5 5
IBTR with axilla 0 1 1
IBTR with distant 4 6 10
Distant alone 17 10 27
Death
All cause 166 168 334
Breast cancer specific 13 8 21
Abbreviations: IBTR, ipsilateral breast recurrence; Tam, tamoxifen alone;

































TamRT 317 261 162 7
Tam 319 252 153 2
Fig 3. Time to subsequent mastectomy. HR, hazard ratio; Tam, tamoxifen



































TamRT 317 260 165 7
Tam 319 254 157 2
Fig 4. Time to distant metastasis. HR, hazard ratio; Tam, tamoxifen alone;
TamRT, tamoxifen plus radiation therapy.
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Noninferiority
The study lacks the power to prove that the trend toward greater
survival (HR, 0.95) and time to mastectomy (HR, 0.50) in the TamRT
group or the trend toward greater breast cancer–specific survival (HR,
1.55) and freedom from distant metastasis (HR, 1.20) in the Tam arm
would not continue.
DISCUSSION
At a median follow-up of 12.6 years, we demonstrate that at 10 years,
the incidence of locoregoreginal recurrence is 8% lower, and the
incidence of IBTR is 7% lower, with TamRT versus Tam alone. This
difference is statistically significant. The addition of RT seems to pro-
vide no benefit in terms of OS, distant disease-free survival, or ultimate
breast preservation, with the proviso that the study lacked the power to
definitively show noninferiority of either arm. Importantly, the study
also shows that the impact of breast cancer in this select group of older
women is much smaller than that of comorbid conditions. Of the 636
women in this study, only 21 (3%) have died as a result of breast
cancer, whereas 313 (49%) have died as a result of other causes (only
6% of deaths attributed to breast cancer).
As breast conservation became an accepted approach in the
1980s, it was thought that there were subgroups of women in whom
RT might be safely eliminated. Several randomized trials were initiated
that compared the efficacy of Tam versus TamRT after lumpectomy
(Appendix Table A2, online only). All were based on the premise that
women at low risk of recurrence might benefit from less treatment.
Trials used varying combinations of postulated low-risk factors, such
as older age, smaller tumors, and tumors with favorable prognostic
factors. Although all of the trials examined the question of eliminating
RT, CALGB 9343 differed from other trials in the factors chosen for
eligibility. The National Surgical Adjuvant Breast and Bowel Project
(NSABP) B21 trial1 was based on tumor size of  1 cm, included
younger women, and had three arms: Tam, TamRT, and RT placebo.
The Austrian Breast and Colorectal Cancer Study Group trial4 had a
mean age of 66 years, tumor size 3 cm, and hormone treatment with
either tamoxifen or anastrazole. The German Breast Cancer Group
trial (GBCG-V)5 allowed women as young as age 45 years and used a
2  2 factorial design (RT or no RT; Tam or no Tam). The British
Association of Surgical Oncology (BASO) BASO II trial2 followed a
similar 2  2 factorial design. Tinterri et al10 randomly assigned
women between the ages of 55 and 75 years to either RT and no RT
but allowed systemic therapy as dictated by tumor characteristics.
Despite the differences in design, no study showed significant
differences in distant disease-free survival or OS, although all
showed some decrease in IBTR with RT. The differences in terms of
eligibility criteria likely account for the differences seen in the effect
of RT on breast recurrence.
CALGB 9343 was originally conceived based on several observa-
tions. First, adjuvant RT after breast-conserving surgery does not
change survival. The Early Breast Cancer Trialists’ Collaborative
Group 2005 meta-analysis11 reported a significant reduction in mor-
tality at 15 years with RT, but it is clear that this only applied if the
difference in IBTR was  10%. Most trials reported here revealed a
difference in IBTR of  10%. The data continue to support no sur-
vival advantage with the addition of adjuvant RT in the cohorts rep-
resented by these trials.
Second, older women have fewer local recurrences. The Milan III
trial12 suggested that with quadrantectomy and axillary dissection
alone, the rate of IBTR decreased with advancing age. Women age
 45 years had a 17.5% rate of IBTR, whereas those age55 years had
a 3.8% rate of IBTR. The trials listed in Appendix Table A2 (online
only) reinforce this finding, demonstrating a trend toward higher
IBTR in younger women with or without RT.
Third, adjuvant Tam after breast conservation decreases the risk
of in-breast recurrence.13 Older women tend to have estrogen-
sensitive tumors,14 and tamoxifen efficacy increases directly with
levels of estrogen receptor expression.15 Tumor estrogen and proges-
terone receptor levels increase over time with maximum expression in
women age  75 years.16 Moreover, when compared with Tam, aro-
matase inhibitors (AIs) seem to show an even further decrease in risk
of IBTR.17 In a meta-analysis of randomized trials comparing 5 years
of either adjuvant Tam or an AI, patients receiving an AI had an HR of
0.70 for isolated local recurrence as a first event (two-sided P  .03).
Fourth, local recurrence after breast-conserving treatment with-




























TamRT 317 264 168 7
Tam 319 262 167 4
Fig 5. Overall survival. HR, hazard ratio; Tam, tamoxifen alone; TamRT,


























Fig 6. Observed versus expected survival.
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with RT. Preservation of the breast, even after IBTR, has been demon-
strated by Liligren et al,18 Clark et al,19 and Veronesi et al.12 In our
study, there was no significant difference in ultimate rate of
breast preservation.
We note that the definition of negative margins has changed
since this study began. CALGB 9343 accepted the NSABP standard of
no ink on tumor, essentially a one-cell minimum margin. Today, the
trend is toward greater negative margins, usually 1 to 2 mm,20,21 and
the low rate of IBTR without RT in this study might further decrease
with wider excision, suggesting that any benefit of RT over antiestro-
gen treatment alone in local recurrence may be of even less signifi-
cance today.
In our study, treatment of the axilla was left to the discretion of
the physician. Among women who did not have an axillary dissection
upfront, none in the TamRT arm experienced recurrence in the axilla;
however, six (3%) in the Tam arm did. In the absence of RT or sentinel
node biopsy, we might expect a 3% increase in local control compared
with RT or sentinel node biopsy. If the results of a sentinel node biopsy
are not likely to change the choice of systemic treatment, it is question-
able whether this 3% decrement warrants the use of sentinel node
biopsy in this population.
Fifth, shorter life expectancy in older women leaves less time for
local recurrence. We anticipated that many women would die as a
result of competing causes in a relatively short period of time and thus
not live long enough to be at risk for IBTR. This was not correct,
because the median survival was 12 years, and yet the rate of IBTR
remained low. We would suggest that in this older population, comor-
bid conditions, not specific breast cancer treatments, dictate survival,
and the biology of the tumor dictates the rate of IBTR, not the length
of life.
Time to distant metastasis did not differ between the two treat-
ment groups and continues to be low. The 10-year incidence of distant
disease was only 5% in the Tam RT group and 5% with Tam alone.
The women in this study were significantly healthier and lived
considerably longer than the general population of that set of ages.
This suggests that the results of this study apply to healthy women in
this age group, not just to those with comorbidities.
The durability of the results of this study is encouraging. When
first presented, there was concern that with longer follow-up, the
number of recurrences would increase. However, the number of
events for both groups remains low. With median follow-up of 12.6
years, 334 of 636 women have died, but only 21 (6%) of these have died
as a result of breast cancer. In comparison with our previous report of
these results at median follow-up of 5 years,6 as expected, the all-cause
mortality proportion has increased, but it is still similar between the
two arms. The 10-year incidence of breast cancer survival is low in
both arms.
The toxicity of tamoxifen is not trivial, particularly in this elderly
population. Well-known adverse effects include hot flashes, throm-
botic events, and a small risk of endometrial cancer.22 However, de-
spite the possibility that all patients were not able to complete the
prescribed course of treatment, local control, distant disease-free sur-
vival, and cancer-specific survival remained excellent in this popula-
tion with generally favorable disease characteristics.
Despite the observed similarity in OS and absolute risk reduction
by breast irradiation in locoregional recurrence of only 7%, this study
has not had a notable impact on clinical practice. The recent article by
Soulos et al7 found that RT use decreased  5% after publication and
dissemination of the data. The decision to use RT may depend more
on concerns about our initial short-term 5-year follow-up, patient
perception of substandard treatment, choosing the length of time for
RT versus tamoxifen, financial considerations, and physician equi-
poise. The editorial by Giordano23 accompanying that article sug-
gested that given the same level of significance, physicians are more
likely to adopt a change in practice that adds or enhances a treatment,
rather than a change in which a treatment is withdrawn.
CALGB 9343 was conceived based on the hypothesis that there
was a subset of patients in NSABP B06 who did not benefit from breast
irradiation after lumpectomy. We observed the indolent behavior of
breast cancer in older women in everyday clinical practice and used
that as the basis for our study design. Our goal was to offer this cohort
of women another treatment option that might decrease morbidity,
allow for adaption to social issues, and not complicate other medical
problems. Our study offers evidence that such women should have the
option of breast-conserving therapy even without RT.
Long-term follow-up of CALGB 9343 confirms and extends the
earlier report that in women age  70 years with clinical stage I,
ER-positive breast cancer treated with lumpectomy followed by ta-
moxifen, irradiation adds no significant benefit in terms of survival,
time to distant metastasis, or ultimate breast preservation, even
though it provides a small decrease in IBTR.
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Appendix
Table A1. Patient Demographic and Clinical Characteristics
Characteristic
TamRT Arm Tam Arm Total
No. % No. % No. %
Treated patients 317 100 319 100 636 100
Stratification
ER status
Positive 313 99 313 98 626 98
Negative 4 1 6 2 10 2
Tumor size, cm
 2 310 98 313 98 623 98
 2 7 2 6 2 13 2
Age at enrollment, years
 75 141 44 147 46 288 45
 75 176 56 172 54 348 55
Demographics
Race
White 287 91 287 90 574 90
Hispanic 5 2 8 3 13 2
Black 23 7 22 7 45 7
Asian 0 0 2 1 2  1
Other 1  1 0 0 1  1
Unknown 1  1 0 0 1  1
Diagnostic axillary involvement
Underwent axillary dissection 122 38 119 37 241 38
Abbreviation: ER, estrogen receptor; Tam, tamoxifen alone; TamRT, tamoxifen plus radiation therapy.












CALGB 9343 636 10.5  70  2.0 Tam 9  .001
TamRT 2
NSABP B211 1,009 8 Any age  1 Tam 17  .001
TamRT 3
RT placebo 9
Winzer et al5 361† 10 45-75  2 Surgery alone 34  .001
Surgery plus RT 10
Surgery  tamoxifen 8
Surgery  RT  tamoxifen 9
Potter et al4 869 4.5 Postmenopausal (mean, 66)  3 Tam or AI 6  .001
Tam or AI  RT 2
Fyles et al3 769 5.6  50  5 Tam 8 .001
TamRT 1
Tinterri et al10 749 5.0 55-75  2.5 Surgery alone 3 .07
Surgery  RT 1
Forrest et al‡ 585 6  70  4 Tam§ 25 NS
TamRT 6
Abbreviations: AI, aromatase inhibitor; CALGB, Cancer and Leukemia Group B; NS, not stated; NSABP, National Surgical Adjuvant Breast and Bowel Project; RT,
radiation therapy; Tam, tamoxifen alone; TamRT, tamoxifen plus radiation therapy.
Locoregional recurrence.
†347 analyzed.
‡Forrest et al: Lancet 348:708-713, 1996.
§Or cyclophosphamide, methotrexate, and fluorouracil based on estrogen receptor status.
Hughes et al



































TamRT 317 264 168 7
Tam 319 262 167 4
Fig A1. Breast cancer–specific survival. HR, hazard ratio; Tam, tamoxifen alone; TamRT, tamoxifen plus radiation therapy.
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